Enanta Pharmaceuticals has announced the filing of a patent infringement suit against Pfizer in the Unified Patent Court of the European Union. The suit concerns the alleged infringement of European Patent No. EP 4 051 265, which involves coronavirus protease inhibitors. Enanta is seeking a determination of liability related to the manufacture, use, and sale of Pfizer's COVID-19 antiviral, Paxlovid. The patent is the European counterpart of a U.S. patent involved in ongoing litigation between the two companies. A hearing in the UPC is expected to take place within 12 months, with a decision to follow shortly thereafter.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。